The biotechnology sector had a decline in 2022 that went beyond just falling stock prices. Additionally, only 37 new drugs were approved by the FDA’s primary review office last year, the lowest number since 2016. Yet there is cause for optimism, as the number of treatments the FDA approves each year might vary. According to […]

The post 5 FDA Announcements To Pay Attention To In The 2023 Q1 first appeared on World Pharma Today.